Melinta Therapeutics, Inc. (MLNT) EPS Estimated At $-1.17

September 30, 2018 - By Mark Babin

Analysts expect Melinta Therapeutics, Inc. (NASDAQ:MLNT) to report $-1.17 EPS on November, 1.After having $-1.38 EPS previously, Melinta Therapeutics, Inc.’s analysts see -15.22 % EPS growth. The stock increased 1.28% or $0.05 during the last trading session, reaching $3.95. About 228,744 shares traded. Melinta Therapeutics, Inc. (NASDAQ:MLNT) has declined 72.06% since September 30, 2017 and is downtrending. It has underperformed by 87.68% the S&P500.

Melinta Therapeutics, Inc., an antibiotics company, is engaged in the discovery, development, and commercialization of antibiotics to overcome drug-resistant, life-threatening infections. The company has market cap of $221.24 million. It develops Delafloxacin, a fluoroquinolone for acute bacterial skin and skin structure infections caused by Gram-positive and Gram-negative bacteria; and Baxdela for the treatment of patients with acute bacterial skin and skin structure infections. It currently has negative earnings. Melinta Therapeutics, Inc. was formerly known as formerly Rib-X Pharmaceuticals and changed its name to Melinta Therapeutics, Inc. on October 7, 2013.

More notable recent Melinta Therapeutics, Inc. (NASDAQ:MLNT) news were published by: which released: “Melinta Therapeutics to Present at Upcoming Investor Conferences” on September 25, 2018, also with their article: “Melinta Therapeutics to Host Meetings at the Morgan Stanley 16th Annual Global Healthcare Conference” published on September 06, 2018, published: “Melinta Therapeutics Receives Positive CHMP Opinion for Vabomereâ„¢ (meropenem and vaborbactam)” on September 21, 2018. More interesting news about Melinta Therapeutics, Inc. (NASDAQ:MLNT) were released by: and their article: “Melinta Therapeutics Names Peter Milligan as Chief Financial Officer” published on September 18, 2018 as well as‘s news article titled: “Premarket analyst action – healthcare” with publication date: September 11, 2018.

Melinta Therapeutics, Inc. (NASDAQ:MLNT) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: